Telomir Pharmaceuticals, Inc.
TELO
$1.22
$0.032.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 130.17% | -31.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 69.47% | -51.22% | |||
| Operating Income | -69.47% | 51.22% | |||
| Income Before Tax | -73.73% | 51.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -73.73% | 51.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -73.73% | 51.93% | |||
| EBIT | -69.47% | 51.22% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -2,630.21% | 53.17% | |||
| Normalized Basic EPS | 1.67% | 53.25% | |||
| EPS Diluted | -2,630.21% | 53.17% | |||
| Normalized Diluted EPS | 1.67% | 53.25% | |||
| Average Basic Shares Outstanding | 76.95% | 2.65% | |||
| Average Diluted Shares Outstanding | 76.95% | 2.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||